Ceribell 3Q 2026: Revenue $29.3M, Net loss $21.4M, EPS $(0.55) — 10-Q Summary

What happened

Ceribell reported third-quarter 2026 revenue of $29.3 million, up 30% year over year, while its net loss widened to $21.4 million from $13.5 million. Diluted loss per share was $0.55, compared with $0.37 a year earlier. Its system was in more than 700 hospitals as of September 30.

Confirmed

Global impact / market context

Revenue growth and wider losses point in different directions: more sales may support expansion, but the larger loss means costs exceeded revenue by more than in the prior-year quarter. Plans to add U.S. sales staff and develop the system could increase costs before generating additional sales.

Analyst inference

The company reported 30% year-over-year revenue growth alongside a larger net loss, while citing hospital deployments and new FDA clearances. For investors, the key tension is whether broader use and product development can translate into enough revenue to narrow losses over time.

Analyst inference

What to watch

1. Watch subsequent revenue and net-loss figures to see whether sales growth continues and whether the gap between revenue and losses narrows or widens. Analyst inference
2. Track whether Ceribell expands its U.S. sales team and obtains additional international regulatory clearances, as the company says it plans to do. Proposed
3. Look for evidence that existing hospitals increase their use of the system and that new FDA-cleared functions support adoption across its deployed base. Analyst inference

Evidence

• Original source link unavailable